Corcept Therapeutics | CORT - Current Assets


Corcept Therapeutics reported $426.03M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Alaunos Therapeutics USD 970K 1.02M Mar/2026
ANI Pharmaceuticals USD 747.08M 6.03M Mar/2026
Ardelyx USD 381.87M 447K Mar/2026
Aurora Cannabis CAD 397.45M 48.38M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Canopy Growth CAD 529.47M 4.8M Mar/2026
Corcept Therapeutics USD 426.03M 59.43M Mar/2026
Eli Lilly USD 54.84B 794M Mar/2026
J&J USD 59.17B 3.55B Mar/2026
Knight Therapeutics CAD 394.84M 5.86M Dec/2025
Lexicon Pharmaceuticals USD 186.03M 84.14M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Novartis USD 26.61B 3.85B Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
Omeros USD 69.65M 26.53M Jun/2025
Pacira USD 514.96M 33.01M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
Supernus Pharmaceuticals USD 731.58M 87.4M Mar/2026
TG Therapeutics USD 1.09B 456.2M Mar/2026